Third Quarter 2026
Filed Nov 2, 2026Tempus Reports Third Quarter 2026 Results
Third-quarter revenue increased 23%, Data and Applications grew 33%, gross profit increased 27%, and Adjusted EBITDA rose to $25.6 million from $1.5 million. The company increased full-year revenue guidance to $1.60 to $1.605 billion while maintaining expected full-year Adjusted EBITDA of ~$65 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total net revenue, three months ended September 30, 2026GAAP | $411.5M | – | 23 % |
| Gross profit, three months ended September 30, 2026GAAP | $266.7M | – | 27 % |
| Gross margin, three months ended September 30, 2026GAAP | 64.8 % | – | – |
| Non-GAAP gross profit, three months ended September 30, 2026non-GAAP | $271.2M | – | – |
| Non-GAAP gross margin, three months ended September 30, 2026non-GAAP | 65.9 % | – | – |
| Technology research and development expense, three months ended September 30, 2026GAAP | $45.71M | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $ 46,000 | – | – |
| Selling, general and administrative expense, three months ended September 30, 2026GAAP | $231.9M | – | – |
| Operating expenses, three months ended September 30, 2026GAAP | $323.6M | – | – |
| Non-GAAP operating expenses, three months ended September 30, 2026non-GAAP | $256.8M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$56.86M | – | 7 % |
| Non-GAAP income (loss) from operations, three months ended September 30, 2026non-GAAP | $14.42M | – | 267 % |
| Net loss, three months ended September 30, 2026GAAP | −$14.85M | – | 81 % |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.08 ) | – | 83 % |
| Non-GAAP net income (loss), three months ended September 30, 2026non-GAAP | $13.36M | – | 168 % |
| Non-GAAP net income (loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP | $ 0.07 | – | 164 % |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $25.57M | – | 1,633 % |
| Total net revenue, nine months ended September 30, 2026GAAP | $1.14B | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $735.2M | – | – |
| Gross margin, nine months ended September 30, 2026GAAP | 64.4 % | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$217.5M | – | – |
| Non-GAAP income (loss) from operations, nine months ended September 30, 2026non-GAAP | $134K | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$135.1M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (0.75 ) | – | – |
| Non-GAAP net income (loss), nine months ended September 30, 2026non-GAAP | −$16.98M | – | – |
| Non-GAAP net income (loss) per share, basic and diluted, nine months ended September 30, 2026non-GAAP | $ (0.09 ) | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $30.78M | – | – |
| Net cash used in operating activities, nine months ended September 30, 2026GAAP | −$71.59M | – | – |
| Purchases of property and equipment, nine months ended September 30, 2026GAAP | −$23.66M | – | – |
| Net cash used in investing activities, nine months ended September 30, 2026GAAP | −$38.68M | – | – |
| Net cash provided by financing activities, nine months ended September 30, 2026GAAP | $96.14M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Diagnostics, three months ended September 30, 2026Driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%. | $303.5M | – | 20% |
| Data and applications, three months ended September 30, 2026Insights grew 29%. | $108.1M | – | 33% |
| Diagnostics, nine months ended September 30, 2026No segment driver was provided for the nine-month period. | $853.9M | – | – |
| Data and applications, nine months ended September 30, 2026No segment driver was provided for the nine-month period. | $288.2M | – | – |
Full year 2026 outlook
- Revenue$1.60 to $1.605 billion
- Note~25% annual growth
- NoteAdjusted EBITDA of ~$65 million
What drove it
- Oncology volume growth accelerated to 32%.
- Minimal Residual Disease volume was ~12,000 tests, up 300%.
- Data and Applications revenue increased 33%, with Insights increasing 29%.
- Growth in Data and Applications led gross-profit growth.
- In October, Tempus announced a BMS collaboration that brought total data licensing bookings to >$550 million year to date.
- Tempus directly licensed oncology data and models to BMS for up to $137.5 million over a five-year term, while BMS and Pathos licensed Alzheimer’s or dementia data for $55 million over a five-year term.
Concerns
- The company recorded a GAAP net loss of $ (14,851 ) in the third quarter and $ (135,128 ) for the nine months ended September 30, 2026.
- GAAP operating expenses were $ 323,565 in the third quarter, including $ 231,857 of selling, general and administrative expense.
- Third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes.
- The company had convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877 at September 30, 2026.
- The pending Personalis acquisition remained subject to shareholder approval, with the shareholder meeting planned for November 30, 2026.
What to watch
- Execution against full-year 2026 revenue guidance of $1.60 to $1.605 billion and expected Adjusted EBITDA of ~$65 million.
- Sustainability of 32% Oncology volume growth, ~12,000 MRD test volume, and 33% Data and Applications revenue growth.
- Commercialization and data-licensing activity under the BMS, Merck, and Moderna collaborations.
- The planned November 30, 2026 Personalis shareholder vote and the potential completion of the acquisition.
- Progress toward building a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years.
Balance sheet and cash flow
- Cash and cash equivalents at September 30, 2026: $ 590,479.
- Marketable equity securities at September 30, 2026: $ 46,874 current and $ 212,276 less current portion.
- Cash and marketable securities at quarter end: $854.4 million.
- Convertible promissory note at September 30, 2026: 175,967.
- Convertible senior notes, net, at September 30, 2026: 1,174,877.
- Revolving credit facility at September 30, 2026: —.
- Long-term debt, net, at September 30, 2026: —.
- Net decrease in cash, cash equivalents and restricted cash for the nine months ended September 30, 2026: $ (14,217 ).
- Proceeds from convertible senior notes, net of initial purchasers' discount, for the nine months ended September 30, 2026: 443,132.
- Principal payments on long-term debt for the nine months ended September 30, 2026: (207,717 ).
- Principal payments on revolving credit facility for the nine months ended September 30, 2026: (100,000 ).
Analysis
Tempus reported third-quarter GAAP revenue of $ 411,537, up 23 % from $ 334,206. Diagnostics generated $ 303,470, with 20% growth driven by Oncology volume growth of 32%, partly offset by Hereditary revenue growth of 3%. Data and applications generated $ 108,067 and grew 33%, while Insights grew 29%. MRD volume was ~12,000 tests, up 300%.
Gross profit rose 27 % to $ 266,701, and GAAP gross margin increased to 64.8 % from 62.8 %. Both major businesses expanded gross margin: Diagnostics gross margin was 62.4 % versus 61.0 %, and Data and applications gross margin was 71.5 % versus 68.5 %. The faster growth of Data and Applications and its higher reported gross margin were central to the gross-profit improvement.
GAAP loss from operations was $ (56,864 ), compared with $ (60,996 ). GAAP operating expenses were $ 323,565, including $ 231,857 of selling, general and administrative expense. On a non-GAAP basis, income from operations was $ 14,422 compared with a loss of $ (8,662 ), and Adjusted EBITDA was $ 25,572 compared with $ 1,476. The GAAP net loss narrowed to $ (14,851 ) from $ (79,982 ), while non-GAAP net income was $ 13,359. The third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities.
For the nine months ended September 30, 2026, total net revenue was $ 1,142,139 and Adjusted EBITDA was $ 30,783. Net cash used in operating activities improved to $ (71,586 ) from $ (181,302 ). At September 30, 2026, cash and cash equivalents were $ 590,479, while marketable equity securities were $ 46,874 current and $ 212,276 less current portion. The balance sheet also reported convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877.
Management increased full-year 2026 revenue guidance to $1.60 to $1.605 billion, representing ~25% annual growth, and continued to expect Adjusted EBITDA of ~$65 million. Commercial activity included the October BMS collaboration, which management said brought total data licensing bookings to >$550 million year to date, as well as a Merck and Moderna collaboration supporting potential commercialization of intismeran autogene. Regulatory review cleared for the pending Personalis acquisition, whose shareholder meeting is planned for November 30, 2026.
Management, verbatim
Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.
Eric Lefkofsky, founder and CEO of Tempus
Not in the filing
stated, not guessed- Prior-quarter comparisons were not reported for the presented operating metrics.
- Free cash flow was not reported.
- Quarterly operating cash flow was not reported.
- Share repurchases were not reported.
- Dividends were not reported.
- Prior guidance was not provided, so comparison with prior guidance is unavailable.
- Guidance for gross margin, operating expenses, and tax rate was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.